AstraZeneca cuts late-stage IL-23 drug due to trial delays, competitive landscape

AstraZeneca is shelving an IL-23 antibody that’s been through a winding journey around pharma — including stops at Amgen and Allergan — and putting an end to Phase II and III trials testing the drug for inflammatory bowel disease. “The decision to discontinue brazikumab’s IBD development follows a recent review…